Further research is needed to clarify whether GIP or GIP-1R agonists can also attenuate intestinal inflammation in IBD [399], and clinical studies further evaluating adverse events associated with GIP/GLP-1 combination therapy are warranted. This evidence concerns the gene GLP1R and inflammatory bowel disease.